Jianwei Wang

Prof. Dr. Jianwei Wang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SLShaoshuo Li
Shaoshuo Li
BCBaixing Chen
Baixing Chen
HCHao Chen
Hao Chen
ZHZhen Hua
Zhen Hua
YSYang Shao
Yang Shao
JWJianwei Wang
Jianwei Wang
Objectives: Smoking is a significant independent risk factor for postmenopausal osteoporosis, leading to genome variations in postmenopausal smokers. This study investigates potential biomarkers and molecular mechanisms of smoking-related postmenopausal osteoporosis (SRPO).Materials and methods: The GSE13850 microarray dataset was downloaded from Gene Expression Omnibus (GEO). Gene modules associated with SRPO were identified using weighted gene co-expression network analysis (WGCNA), protein-protein interaction (PPI) analysis, and pathway and functional enrichment analyses. Feature genes were selected using two machine learning methods: support vector machine-recursive feature elimination (SVM-RFE) and random forest (RF). The diagnostic efficiency of the selected genes was assessed by gene expression analysis and receiver operating characteristic curve.Results: Eight highly conserved modules were detected in the WGCNA network, and the genes in the module that was strongly correlated with SRPO were used for constructing the PPI network. A total of 113 hub genes were identified in the core network using topological network analysis. Enrichment analysis results showed that hub genes were closely associated with the regulation of RNA transcription and translation, ATPase activity, and immune-related signaling. Six genes (HNRNPC,PFDN2,PSMC5,RPS16,TCEB2, andUBE2V2) were selected as genetic biomarkers for SRPO by integrating the feature selection of SVM-RFE and RF.Conclusion: The present study identified potential genetic biomarkers and provided a novel insight into the underlying molecular mechanism of SRPO.

26 March 2021 in Medicine
Verified
Journal Article
Open access
SLShaoshuo Li
Shaoshuo Li
BCBaixing Chen
Baixing Chen
ZHZhen Hua
Zhen Hua
YSYang Shao
Yang Shao
HYHeng Yin
Heng Yin
JWJianwei Wang
Jianwei Wang
Background: Topical hemostatic agents are commonly used for reducing perioperative blood loss and transfusion requirement in primary total knee arthroplasty (TKA), although the optimal option has yet to be defined. This study aimed to evaluate the efficacy and safety of topical hemostatic agents and rank the best intervention using the network meta-analysis (NMA) method. Methods: We searched Web of science, PubMed, and Cochrane Library database up to April 2020, for randomized controlled trials (RCTs) on topical hemostatic agents in primary TKA. The quality of included studies was assessed using the Cochrane “risk of bias” tool. Direct and indirect comparisons were performed for the result of network meta-analysis followed by consistency test. Results: Thirty seven RCTs with 3792 patients were included in this NMA and the pooled results indicated that tranexamic acid plus diluted epinephrine (TXA+DEP) displayed the highest efficacy in reducing total blood loss, hemoglobin drop and transfusion requirement. None of the included treatments was found to increase risk of thromboembolic events compared to placebo. According to the results of ranking probabilities, TXA+DEP had the highest possibility to be the best topical hemostatic agent with regard to the greatest comparative efficacy and a relatively high safety level. Conclusion: Current evidence supports that administration of TXA+DEP may be the optimal topical hemostatic agent to decrease blood loss and transfusion requirement in primary TKA. More direct studies that focused on the topical application of TXA+DEP versus other treatments are needed in the future.

18 November 2025 in Journal of Orthopaedic Surgery and Research
Verified
Journal Article
Open access
XSXueqiang Shen
Xueqiang Shen
PYPengfei Yu
Pengfei Yu
YSYang Shao
Yang Shao
JLJintao Liu
Jintao Liu
HJHong Jiang
Hong Jiang
JWJianwei Wang
Jianwei Wang
Background Although contrast-enhanced magnetic resonance imaging (MRI) appears to have value for predicting resorption of ruptured lumbar disc herniation (LDH), prospective studies are lacking and confirmation is warranted. Methods A single-center prospective study was conducted to evaluate the value of contrast-enhanced MRI for predicting ruptured LDH resorption from January 2024 to May 2025. 90 patients with ruptured LDH were enrolled, and 82 patients were included for analysis. All patients underwent contrast-enhanced MRI to classify the type of enhancement: type I, the enhancement completely surrounds the herniated intervertebral disc (IVD) (complete bull's sign); type II, the enhancement only partially surrounds the herniated IVD (partial bull's sign); and type III, no enhancement around the herniated IVD. After 9 months of follow-up, changes in the Oswestry Disability Index (ODI) score and resorption rate were calculated. Results 25 patients (30.49%) underwent surgical treatment, while 57 (69.51%) completed non-surgical treatment without requiring surgery. In the non-surgical group, the enhancement type was as follows: type I, 27 patients; type II, 14 patients; and type III, 16 patients. Resorption occurred in 81.48% of patients with type I enhancement, 50% of patients with type II, and 0 patient with type III. The resorption rate significantly differed between the patients with types I, II, and III enhancement (52.46% ± 26.94%, 44.26% ± 38.04%, and 8.86% ± 13.81%, respectively; F = 13.171; p < 0.001). Conclusion Patients with ruptured LDH can achieve clinical symptom relief with non-surgical treatment, and some patients may experience resorption. Contrast-enhanced MRI shows value for predicting resorption in ruptured LDH.

27 February 2022 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
SLShaoshuo Li
Shaoshuo Li
YSYang Shao
Yang Shao
HCHao Chen
Hao Chen
JWJianwei Wang
Jianwei Wang
Objective. To identify the potential pharmacological targets of Jisuikang (JSK) for the treatment of spinal cord injury (SCI) using network pharmacology. Methods. The bioactive compounds of JSK herbs and their corresponding potential SCI targets were obtained from three traditional Chinese medicine (TCM) databases. SCI-related therapeutic target genes were obtained from the Comparative Toxicogenomics Database and the GeneCards Database. The common target genes between the JSK compounds and SCI-related therapeutic targets were screened using GO/KEGG functional enrichment and protein-protein interaction (PPI) analyses to identify hub genes and their categories of biological function. Gene expression distribution and receiver operating characteristic curve (ROC) analyses were used to identify probable SCI-related target genes. Molecular docking was used to quantify molecular interactions between target genes and the bioactive compounds of JSK. Results. A total of 183 JSK bioactive compounds and 197 target genes for the treatment of SCI were screened and assessed. The target genes were enriched primarily in drug metabolism and in inflammation-related biological processes. Ten genes with statistical significance were identified as therapeutic SCI-related target genes of JSK. Molecular docking experiments demonstrated that the proteins of these 10 genes docked with binding energies of less than 5kcal/mol with the bioactive compounds in JSK. Conclusion. This study showed that the anti-SCI effects of JSK may be mediated through numerous bioactive components, multiple gene targets, and inflammation-related pathways and provided potential novel targets for directed therapies for treating SCI. These results provide a foundation for further experimental investigations into treatment options for SCI.

28 April 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
YZYi Zhou
Yi Zhou
SLShaoshuo Li
Shaoshuo Li
BHBowen Hong
Bowen Hong
ZWZihan Wang
Zihan Wang
YSYang Shao
Yang Shao
JWJianwei Wang
Jianwei Wang
Background: Osteoporosis (OP) represents a widespread bone remodeling disorder within the domain of orthopedics, markedly compromising the quality of life in the elderly population. The need to develop more efficient therapeutic approaches to attenuate bone resorption by suppressing the excessive activation of osteoclasts (OCs) remains urgent. The plant flavonoid Isorhamnetin (Iso), recognized for its potent antioxidant properties, has been the subject of extensive research regarding its potential in treating bone-related conditions.Method: This study adopts a comprehensive methodology to evaluate Iso’s impact on bone metabolism and its therapeutic possibilities for treating OP. By integrating network pharmacology, molecular dynamics simulations, and surface plasmon resonance (SPR), we performed in vitro phenotypic analyses to systematically evaluate the inhibitory effect of Iso on OC differentiation. The mechanisms behind Iso’s inhibition of OC differentiation were further elucidated. In vivo testing was also performed to substantiate the therapeutic effects of Iso in an OP animal model.Results: At low concentrations, Iso showed no cytotoxicity and did not interfere with cell proliferation in RAW 264.7 cells. Iso effectively inhibited RANKL-induced osteoclast differentiation in these cells, while downregulating related genes levels (Nfatc1, Ctsk, Trap, c-Fos). Molecular dynamics simulations and surface plasmon resonance confirmed Iso’s dual binding to both RANKL and RANK. KEGG pathway enrichment analysis results indicated that Iso modulates the MAPK, NF-κB/PI3K-AKT, and calcium signaling pathways. Western blot analysis revealed that Iso treatment targeting the RANKL/RANK binding pathway significantly downregulated phosphorylation levels of JNK, P38, AKT, and p65. Concurrently, Iso stimulation markedly increased IκBα expression, thereby rescuing its degradation. Furthermore, Iso demonstrated a robust inhibitory effect on reactive oxygen species levels in vitro. Furthermore, in OVX mice, Iso treatment increased bone density, modulated serum bone metabolism markers, and downregulated transcriptional levels of OC marker genes.Conclusion: Iso exhibits therapeutic potential for OP by selectively targeting and disrupting the RANKL-RANK interaction. This intervention modulates the expression of intracellular transcription factors and multiple signaling pathways, thereby inhibiting the maturation of OCs. Through mitigating OC-mediated bone loss, Iso holds significant promise as a potent therapeutic agent for OP.

11 May 2023 in Frontiers in Molecular Biosciences
Verified
Journal Article
Open access
HWHaotian Wang
Haotian Wang
SLShaoshuo Li
Shaoshuo Li
BCBaixing Chen
Baixing Chen
MWMao Wu
Mao Wu
HYHeng Yin
Heng Yin
JWJianwei Wang
Jianwei Wang
Objectives: Cigarette smoking has been recognized as a predisposing factor for both osteoporosis (OP) and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the shared gene signatures affected by cigarette smoking in OP and COPD through gene expression profiling.Materials and methods: Microarray datasets (GSE11784, GSE13850, GSE10006, and GSE103174) were obtained from Gene Expression Omnibus (GEO) and analyzed for differentially expressed genes (DEGs) and weighted gene co-expression network analysis (WGCNA). Least absolute shrinkage and selection operator (LASSO) regression method and a random forest (RF) machine learning algorithm were used to identify candidate biomarkers. The diagnostic value of the method was assessed using logistic regression and receiver operating characteristic (ROC) curve analysis. Finally, immune cell infiltration was analyzed to identify dysregulated immune cells in cigarette smoking-induced COPD.Results: In the smoking-related OP and COPD datasets, 2858 and 280 DEGs were identified, respectively. WGCNA revealed 982 genes strongly correlated with smoking-related OP, of which 32 overlapped with the hub genes of COPD. Gene Ontology (GO) enrichment analysis showed that the overlapping genes were enriched in the immune system category. Using LASSO regression and RF machine learning, six candidate genes were identified, and a logistic regression model was constructed, which had high diagnostic values for both the training set and external validation datasets. The area under the curves (AUCs) were 0.83 and 0.99, respectively. Immune cell infiltration analysis revealed dysregulation in several immune cells, and six immune-associated genes were identified for smoking-related OP and COPD, namely, mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), tissue-type plasminogen activator (PLAT), sodium channel 1 subunit alpha (SCNN1A), sine oculis homeobox 3 (SIX3), sperm-associated antigen 9 (SPAG9), and vacuolar protein sorting 35 (VPS35).Conclusion: The findings suggest that immune cell infiltration profiles play a significant role in the shared pathogenesis of smoking-related OP and COPD. The results could provide valuable insights for developing novel therapeutic strategies for managing these disorders, as well as shedding light on their pathogenesis.